PTAB Mulls Validity Of Novartis Syringe IP In Regeneron Fight
By Britain Eakin · July 21, 2022, 7:44 PM EDT
The Patent Trial and Appeal Board on Thursday considered whether Novartis can beat an invalidity challenge from Regeneron over a pre-filled eye injection syringe patent with an argument that skilled artisans...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login